Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting

Bronchial Cancer Clinical Trial

— CombHADom  

Official title:

Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - CombHADom

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04802902
• Other study ID #: CHPAU2021/03
• Status: Completed
• Start date: September 29, 2021
• Est. completion date: February 8, 2024

Study information

• Verified date: February 2024
• Source: Centre Hospitalier de PAU
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy-chemotherapy combo for bronchial cancer in maintenance phase of first row metastatic treatment. The feasibility in good conditions of this management, the patients' quality of life and their satisfaction will be evaluated. A cost-benefit analysis will be done to compare hospital-at-home programme and classical day hospitalization.

Description:

Those last years, immunotherapy treatment for bronchial cancers allowed considerable progress in terms of tumoral answer, survival without progression and global survival. Usually administered in the day hospitalization department, its preparation and administration to the patient are compatible with hospital-at-home management. This type of management has particularly developed in the context of the COVID pandemic and recommendations for good practices in hospital-at-home immunotherapy have recently been drafted by FITC (Société Française d'Immuno-Thérapie du Cancer). These recommendations open the way for administration of immunotherapy and chemotherapy combo in hospital-at-home. At the moment, there is no study stating the feasibility of home hospitalization for patients treated by immunotherapy-chemotherapy combo. To follow up on the feasibility study of home immunotherapy (ImHADom) carried out at CH Pau from March 2019 to March 2021, the sponsor propose to evaluate with descriptive study the feasibility under the same conditions of chemotherapy-immunotherapy in patients treated in the maintenance phase of a first metastatic row. This study will be proposed to all the patients in maintenance phase of first row treatment with at least one positive tumoral imaging assessment (stable disease or partial response) for whom home hospitalization has been decided and scheduled by the healthcare team in a medical staff meeting. The patients included in the study will be followed according to the common practice: a consultation every 3 months during 1 year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 8, 2024
• Est. primary completion date: February 8, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 18 and over,
• with bronchial metastatic cancer treated in first row maintenance phase by immunotherapy-chemotherapy combo,
• having at least one assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response),
• without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy
• eligible for a home-based hospitalization

Exclusion Criteria:

• Frail patients requiring a frequent medical assessment thus day hospitalization cares

Related Conditions & MeSH terms

• Bronchial Cancer
• Carcinoma, Bronchogenic

Intervention

Other:
• home-based hospitalization
management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer

Locations

Country	Name	City	State
France	Centre hospitalier de pau	Pau	Aquitaine

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier de PAU

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of home-based immunotherapy (percentage of patients who interrupted their home hospitalization for reasons directly linked to that management)	Feasibility under good conditions of home-based immunotherapy, defined by the percentage of patients who interrupted their home hospitalization for reasons directly linked to that management.	1 year
Secondary	Cost-benefit analysis	A cost-benefit analysis comparing hospital-at-home programme and classical day hospitalization	1 year
Secondary	Number of adverse effects occuring during the study	Immunotherapy related adverse effects monitoring criteria evaluation	1 year
Secondary	Number of Incidents occurring during the Hospital at Home program handling process	The occurrence of possible incidents related to the Hospital at Home program will be collected at each home based hospitalization.	1 year
Secondary	Quality of Life Questionnaire (EORTC QLQ-C30) total score	To study the patient's reported quality of life before and throughout therapy. Quality of life score obtained through self-administered EORCT QLQ-C30 questionnaire at inclusion, month 3, 6 9 and 12.	at inclusion, month 3, 6 9 and 12
Secondary	Patients' Satisfaction Questionnaire	Patients' satisfaction with their home base management will be assessed with a questionnaire. It will be collected at month 3, 6 9 and 12	at month 3, 6 9 and 12
Secondary	Healthcare professional satisfaction	Healthcare professional satisfaction will be assessed with a questionnaire. It will be collected at month 6, 12, 18 and 24 of the study	at month 6, 12, 18 and 24 of the study